SLC16A7 and neoplasm: Upon immunolocalization of MCT1 together with peroxisomal markers, we have observed a small degree of co-localization with the peroxisomal marker (Fig.2A) in the tumour cell lines (5.15% of the MCT2 co-localizes with the peroxisomal marker in 22RV1 cells and 4% in PC3 cells).